Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (341-350 of 1,126) with videos related to

Pageof 113
Sort By:
BJU International|March 12, 2014
The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based studyGiorgio Gandaglia, Maxine Sun, Ioana Popa, et al.
World Journal of Urology|May 3, 2018
Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancerMarco Bandini, Michele Marchioni, Felix Preisser, et al.
World Journal of Urology|November 1, 2016
Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancerKatharina Boehm, Paolo Dell'Oglio, Zhe Tian, et al.
The Journal of Urology|July 27, 2019
Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney CancerAngela Pecoraro, Carlotta Palumbo, Sophie Knipper, et al.
BJU International|February 26, 2008
Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosisJean-Simon Diallo, Abdulhadi Aldejmah, Abdelali Filali Mouhim, et al.
Urologic Oncology|July 30, 2021
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancerMike Wenzel, Charles Dariane, Fred Saad, et al.
Clinical Pharmacokinetics|September 11, 2014
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancerKim Stuyckens, Fred Saad, Xu Steven Xu, et al.
Cancers|July 27, 2022
Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-UpKevin Kaulanjan, Danny Lavigne, Fred Saad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After NephrectomyCarlotta Palumbo, Francesco A Mistretta, Sophie Knipper, et al.
BMC Cancer|January 8, 2019
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access programAxel Heidenreich, Silke Gillessen, Daniel Heinrich, et al.
Pageof 113

Showing results (341-350 of 1,126) with videos related to

Sort By:
Pageof 113
BJU International|March 12, 2014
The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based studyGiorgio Gandaglia, Maxine Sun, Ioana Popa, et al.
World Journal of Urology|May 3, 2018
Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancerMarco Bandini, Michele Marchioni, Felix Preisser, et al.
World Journal of Urology|November 1, 2016
Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancerKatharina Boehm, Paolo Dell'Oglio, Zhe Tian, et al.
The Journal of Urology|July 27, 2019
Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney CancerAngela Pecoraro, Carlotta Palumbo, Sophie Knipper, et al.
BJU International|February 26, 2008
Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosisJean-Simon Diallo, Abdulhadi Aldejmah, Abdelali Filali Mouhim, et al.
Urologic Oncology|July 30, 2021
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancerMike Wenzel, Charles Dariane, Fred Saad, et al.
Clinical Pharmacokinetics|September 11, 2014
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancerKim Stuyckens, Fred Saad, Xu Steven Xu, et al.
Cancers|July 27, 2022
Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-UpKevin Kaulanjan, Danny Lavigne, Fred Saad, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After NephrectomyCarlotta Palumbo, Francesco A Mistretta, Sophie Knipper, et al.
BMC Cancer|January 8, 2019
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access programAxel Heidenreich, Silke Gillessen, Daniel Heinrich, et al.
Pageof 113